Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

(2395)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancials 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
1569 1537 1579 1543 1515 Last
1611900 1245100 851900 719700 715900 Volume
-2.85% -2.04% +2.73% -2.28% -1.81% Change
Estimated financial data (e)
Sales 2020 14 561 M 128 M 128 M
Net income 2020 2 550 M 22,5 M 22,5 M
Net Debt 2020 9 673 M 85,2 M 85,2 M
P/E ratio 2020 8,62x
Yield 2020 0,95%
Sales 2021 15 110 M 133 M 133 M
Net income 2021 3 661 M 32,3 M 32,3 M
Net Debt 2021 5 399 M 47,6 M 47,6 M
P/E ratio 2021 7,95x
Yield 2021 1,43%
Capitalization 63 073 M 555 M 556 M
EV / Sales 2020 2,17x
EV / Sales 2021 2,28x
Nbr of Employees 1 005
Free-Float 48,8%
More Financials
Company
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. is a Japan-based company mainly engaged in the provision of clinical trials and drug development services for pharmaceutical companies. The Company has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in... 
More about the company
All news about SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
11/03Supplementary Material on 1H Financial Results
PU
11/02Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for t..
CI
11/02Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Full Year ..
CI
11/02Shin Nippon Biomedical Laboratories, Ltd. Reports Consolidated Earnings Results for the..
CI
10/21SHIN NIPPON BIOMEDICAL LABORATORIES : Notice Regarding Revisions of the Earnings Forecasts..
PU
10/21Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for th..
CI
08/27SHIN NIPPON BIOMEDICAL LABORATORIES : Notice Regarding Establishment of SDGs Committee
PU
08/06Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for t..
CI
08/06Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for the Full Year ..
CI
08/06Shin Nippon Biomedical Laboratories, Ltd. Reports Consolidated Earnings Results for the..
CI
08/06Shin Nippon Biomedical Laboratories, Ltd. Revises Consolidated Earnings Guidance for th..
CI
03/30SHIN NIPPON BIOMEDICAL LABORATORIES, : Ex-dividend day for final dividend
FA
03/30SHIN NIPPON BIOMEDICAL LABORATORIES, : Ex-dividend day for extraordinary dividend
FA
03/03Satsuma Pharmaceuticals, Inc. announced that it has received $80 million in funding fro..
CI
02/26Satsuma Pharmaceuticals, Inc. announced that it expects to receive $80 million in fundi..
CI
More news
News in other languages on SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
11/02Shin Nippon Biomedical Laboratories, Ltd. fournit des prévisions de dividendes pour l'a..
11/02Shin Nippon Biomedical Laboratories, Ltd. fournit des prévisions de bénéfices consolidé..
10/21Shin Nippon Biomedical Laboratories, Ltd. révise ses prévisions de bénéfices consolidés..
08/06Shin Nippon Biomedical Laboratories, Ltd. fournit des prévisions de bénéfices consolidé..
08/06Shin Nippon Biomedical Laboratories, Ltd. fournit des prévisions de dividendes pour l'a..
More news
Chart SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Duration : Period :
Shin Nippon Biomedical Laboratories, Ltd. Technical Analysis Chart | 2395 | JP3379950003 | MarketScreener
Technical analysis trends SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Managers and Directors
Ryoichi Nagata Chairman, President & Chief Executive Officer
Shinji Nitanda Chief Financial Officer & Senior Managing Director
Shunji Haruta Executive Officer & Research Manager
Ken Takanashi COO, Representative Director & Vice President
Terumasa Hirai Senior Executive Officer & Head-Compliance
Sector and Competitors
1st jan.Capi. (M$)
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.124.44%566
MODERNA, INC.153.98%107 578
LONZA GROUP AG25.98%56 683
IQVIA HOLDINGS INC.46.84%50 262
SEAGEN INC.-16.63%26 699
CELLTRION, INC.-43.31%23 888